Live and On-Demand Activities

Filter Activities

Clear

Chair's Take on Advances in Gynecologic Cancer Care: Exploring New Advances and Innovative Therapies in Endometrial and Cervical Cancers

0.50 hr(s) | ABIM , CME , MOC

Specialty: Gynecology , Oncology

Therapeutic Area(s): Oncology

Release Date: June 16, 2020

Expiration Date: June 15, 2021

Location: Internet Activity Enduring

Watch Dr. Duska provide a brief recap of recent developments in endometrial and cervical cancer management, including evidence presented at the 2020 American Society of Clinical Oncology Annual Meeting. Dr. Duska comments on these findings and offers thoughts on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancer.

Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

0.50 hr(s) | ABIM , CME , MOC

Specialty: Biomarkers , Immunotherapies

Therapeutic Area(s): Oncology

Release Date: June 15, 2020

Expiration Date: June 14, 2021

Location: Internet Activity Enduring

In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC.

Finding the Path to Clinically Meaningful Outcomes Among Expanding Treatment Options in Renal Cell Carcinoma

1.00 hr(s) | ABIM , CME , CPE , MOC

Specialty: Renal Cell Carcinoma

Therapeutic Area(s): Oncology , Urology

Release Date: June 12, 2020

Expiration Date: June 11, 2021

Location: Internet Activity Enduring

In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky.

Chair's Take: Review of the Latest HCC Therapy Advancements

0.50 hr(s) | ABIM , CME , MOC

Specialty: Hepatocellular Carcinoma

Therapeutic Area(s): Oncology

Release Date: June 12, 2020

Expiration Date: June 11, 2021

Location: Internet Activity Enduring

In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes.

Chair's Take on Cancer-Associated VTE: Highlights From Recent Science

0.50 hr(s) | ABIM , CME , CPE , MOC

Specialty: Oncology

Therapeutic Area(s): Cardiology , Hematology, Benign , Oncology , Vascular Medicine

Release Date: June 11, 2020

Expiration Date: June 10, 2021

Location: Internet Activity Enduring

Dr. Alok Khorana provide a brief recap of recent developments with DOACs in cancer-associated VTE, including evidence presented at the American Society of Clinical Oncology 2020 Annual Meeting. Dr. Khorana comments on these findings and offers thoughts on how to integrate novel oral anticoagulants for personalized management of patients with elevated-risk malignancies such as gastrointestinal and hematologic cancers, among others.

Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team

0.50 hr(s) | ABIM , CME , MOC

Specialty: Oncology

Therapeutic Area(s): Oncology , Thoracic surgery

Release Date: June 10, 2020

Expiration Date: June 9, 2021

Location: Internet Activity Enduring

In this activity, Brendon Stiles, MD, provides a brief recap of the latest advances in the use of immunotherapy as a component of multimodal lung cancer care in locally advanced and earlier stages of NSCLC. He highlights some of the newest data from clinical trials and shares his perspective on the promise and implications of the transition of immune checkpoint inhibitor therapy into curative intent settings of lung cancer.

Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

1.50 hr(s) | CME

Specialty: Genetics

Therapeutic Area(s): Cardiology , Endocrinology , Genetics / genetic disorders , Hematology, Benign , Hepatology , Pediatrics , Pulmonology

Release Date: June 4, 2020

Expiration Date: June 3, 2021

Location: Internet Activity Enduring

Chronic visceral acid sphingomyelinase deficiency (ASMD), also referred to as Niemann-Pick disease type B, is a rare and progressive autosomal recessive lysosomal storage disorder that causes progressive accumulation of sphingomyelin and other lipids in tissues throughout the body and is associated with significant morbidity and reduced life expectancy. The diagnosis of chronic visceral ASMD is often delayed by months or years, because its complex signs and symptoms overlap with other diseases. In this activity, leading experts review current consensus recommendations for the diagnosis of ASMD in pediatric and adult patients. The faculty also review the latest safety, efficacy, and tolerability data on emerging therapies and explore patient cases to offer practical strategies on how to optimally manage patients with chronic visceral ASMD.

Achieving Consensus on Modern VOD/SOS Management: A Guide to Disease Recognition, Classification, and Treatment in Adults and Pediatric Patients

0.75 hr(s) | CME

Specialty: Oncology , SOS , VOD

Therapeutic Area(s): Hematology, Benign , Oncology , Transplant

Release Date: June 4, 2020

Expiration Date: June 3, 2021

Location: Internet Activity Enduring

In this activity, an expert in hematology discusses the recognition, classification, and treatment of adult and pediatric patients with veno-occlusive disease and sinusoidal obstruction syndrome.

CAR T-CELL THERAPY: A ROAD MAP FOR NURSES

1.5 hr(s) | NCPD

Therapeutic Area(s): CAR T

Release Date: January 19, 2021

Expiration Date: January 19, 2022

Location: Internet Activity Enduring Material

Nurses from three cancer centers discuss the nurse's role in preparing patients and caregivers for the CAR T-cell treatment process, assessment, monitoring for and managing side effects, and communication with the patient's community healthcare team to transition patient care back. Following a patient from initial treatment discussion, participants will be able to provide patient care for the case, in this interactive session. With CAR T-cell therapy and follow-up care expanding beyond the major centers, nurses are essential members of the treatment team.

Advances in Treatment for Chronic Lymphocytic Leukemia (CLL)

1.50 hr(s) | No CE Offered , Patient Education

Specialty: Leukemia

Therapeutic Area(s): Chronic Lympoblastic Leukemia (CLL) , Hematology, Benign

Release Date: April 7, 2021

Expiration Date: April 7, 2021

Location: TeleWeb

This telephone and web presentation for patients and caregivers will occur on April 7, 2021 from 1:00 pm to 2:30 pm Eastern Time.

1 12 13 14
Copy link
Powered by Social Snap